CytoReason Company Profile
CytoReason, founded in 2016 and headquartered in Tel Aviv, is a private healthcare technology company specializing in cell-based computational models and machine learning to simulate human disease at the cellular level, enabling pharmaceutical companies to develop targeted therapies, with $123 million raised to date including a recent $80 million Series B1 round, and backed by investors such as M&G, Nvidia, Thermo Fisher Scientific, and Pfizer.
Overview
CytoReason is a provider of cell-based models and data analysis services aimed at developing a computational model of the human body that simulates human disease at the cellular level. The company's platform utilizes proprietary data and machine learning models to reconstruct cellular information from bulk tissue, train an immune-specific engine, and integrate multi-omics data. This approach generates a mechanistic understanding of the immune system, enabling pharmaceutical companies to discover and develop targeted therapies for patients.
- Year Founded: 2016
- Status: Private
- Employees: 129 (as of 2025)
- Latest Deal Type: Series B1
- Latest Deal Amount: $80M
- Total Funding Raised: $123M
- Investors: 10
- Headquarters: Azrieli Circular Tower, 16th floor, Derech Menachem Begin 132, Tel Aviv 6701101, Israel
- Primary Industry: Discovery Tools (Healthcare)
- Other Industries: Pharmaceuticals and Biotechnology
- Verticals: Big Data, Digital Health, Artificial Intelligence & Machine Learning, HealthTech, Life Sciences, Oncology
Valuation & Funding
- Series B1 (Later Stage VC): $80M (15-Jul-2024)
- Series B (Later Stage VC): (27-Oct-2022)
- Series A1 (Later Stage VC): $9.5M (16-Nov-2021), Raised to Date: $19.5M
- Series A (Early Stage VC): $10M (01-Jan-2020), Raised to Date: $10M
Cap Table (Selected)
- A1 Preferred: 13,825,800 shares, Issue Price: $0.69, Liquidation Preference: 1x, % Owned: 8.66%
- A Preferred: 26,373,232 shares, Issue Price: $0.38, Liquidation Preference: 1x, % Owned: 8.55%
Investors (Selected)
- M&G (Asset Manager)
- Nvidia (Corporation)
- Thermo Fisher Scientific (Corporation)
- Pfizer (Pharmaceuticals) (Corporation)
- Asymmetry Ventures (Venture Capital)
Competitors
- Protai Bio (Venture Capital-Backed, Ramat Gan, Israel)
- Quris AI (Venture Capital-Backed, Tel Aviv, Israel)
- Pepticom (Venture Capital-Backed, Jerusalem, Israel)
Frequently Asked Questions
When was CytoReason founded?
CytoReason was founded in 2016.
Where is CytoReason headquartered?
CytoReason is headquartered in Tel Aviv, Israel.
What is the size of CytoReason?
CytoReason has 129 total employees.
What industry is CytoReason in?
CytoReason’s primary industry is Discovery Tools (Healthcare).
Is CytoReason a private or public company?
CytoReason is a private company.
How much funding has CytoReason raised over time?
CytoReason has raised $123M.
Who are CytoReason’s investors?
M&G, Nvidia, Thermo Fisher Scientific, Pfizer (Pharmaceuticals), and Asymmetry Ventures are among the investors in CytoReason.
Who are CytoReason’s competitors?
Protai Bio, Quris AI, and Pepticom are competitors of CytoReason.